Navigation Links
Lentigen Awarded Phase I STTR Grant for Hunter Syndrome
Date:5/18/2010

GAITHERSBURG, Md., May 18 /PRNewswire/ -- Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business technology transfer (STTR) grant for a program on "Lentiviral Gene Therapy for Mucopolysaccharidosis." In this program, Lentigen will collaborate with Dr. R. Scott McIvor Professor, Department of Genetics, Cell Biology and Development, and Dr. Walter Low, Professor, Departments of Neurosurgery and Physiology at the University of Minnesota, Minneapolis, MN.

Hunter syndrome (Mucopolysaccharidosis type II, MPS II) is a rare X-linked recessive, inherited lysosomal storage disorder with an onset at 2-4 years of age.  It has been estimated to affect approximately 1 in 155,000 live male births.  It is caused by the absence of iduronate-2-sulfatase, resulting in systemic accumulation of glycosaminoglycans. Affected individuals suffer from skeletal abnormalities, organomegaly, life-threatening obstructive airway disease, and, in the severely enzyme deficient form, neurologic degeneration and death by age 15. The University of Minnesota is a world-leading center for the treatment of lysosomal storage diseases by hematopoietic stem cell transplantation.

The goal of this program is to evaluate the feasibility of using lentiviral vectors to restore the missing gene in patient's cells and return the cells back to the patient.  The specific research that will be conducted under this grant will use a mouse model of MPS II created in the laboratory of Dr. Joseph Muenzer, University of North Carolina, to establish and test conditions for introduction of the correcting gene and its effectiveness when reintroduced into the animals.

"The demonstrated safety and effectiveness of lentiviral vectors to mediate gene transfer into hematopoietic stem cells and provide clinical benefit in patients with Adrenoleukodystrophy (Lorenzo Oil's disease), as reported in the journal Science in November 2009, makes them the vector of choice for this application" stated Dr. Boro Dropulic, Lentigen's President and Chief Scientific Officer.  "This project is consistent with our strategy of applying Lentigen's technology in diseases of high unmet therapeutic need."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and bioproduction applications. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications. Collaborations include The National Institutes of Health, PATH, IAVI, Harvard Medical School, Expression Therapeutics, Epixis SA, The University of Pennsylvania, The Johns Hopkins University, Case Western Reserve University, The Medical College of South Carolina, The University of Pittsburgh and The U.S. Army. For further information, visit www.lentigen.com.


'/>"/>
SOURCE Lentigen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
3. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
4. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
5. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
6. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
7. Lentigen Appoints Jim Meade as Vice President of Corporate Development
8. Lentigen Corporation Announces Relocation to New Facility
9. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
10. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
11. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... its GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. ... and utilizing the experience of both in-house personnel and consultants, VetStem constructed and ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 /PRNewswire/ ... that apatorsen results from two randomized Phase 2 clinical trials ... 2017 Genitourinary Cancers Symposium, held February 16 th - 18 ... from trials in bladder and prostate cancers demonstrated apatorsen was ... standard-of-care treatments. ...
(Date:2/21/2017)... 21, 2017   Logicalis Healthcare Solutions , the ... and managed services provider ( www.us.logicalis.com ), today announced ... Epic. The new service will help hospital CIOs make ... giving physicians, nurses and other clinicians immediate access to ... This will allow hospital IT staff to focus on ...
(Date:2/21/2017)... , Feb. 21, 2017   Invitae Corporation ... information companies, today announced that members of the company,s ... 37th Annual Health Care Conference on Monday, March 6, ... Pacific in Boston, Massachusetts . ... may be accessed by visiting the investors section of ...
Breaking Biology Technology:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... The global synthetic-biology market ... billion by 2021, growing at a compound annual growth rate ... overview of the global markets for synthetic biology. - Analyses ... 2016, and projections of compound annual growth rates (CAGRs) through ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):